The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Share News (GNS)

Share Price Information for Genus (GNS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,892.00
Bid: 1,896.00
Ask: 1,902.00
Change: 12.00 (0.64%)
Spread: 6.00 (0.316%)
Open: 1,876.00
High: 1,910.00
Low: 1,876.00
Prev. Close: 1,880.00
GNS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Genus shares plunge as expects adjusted profit and revenue decline

Thu, 15th Feb 2024 09:41

(Alliance News) - Genus PLC on Thursday warned that Chinese porcine markets continued to be "challenging", as it anticipates reporting lower revenue and adjusted pretax profit for its recent half-year.

Shares in the Basingstoke, England based animal genetics biotechnology company focused on cattle and pig farms plunged 30% to 1,478.00 pence each on Thursday morning in London.

Genus expects to report adjusted pretax profit for the financial first-half ended December 31 of GBP29 million on revenue of GBP334 million.

Both outcomes will be in line with expectations, but they would represent a 31% slump in adjusted pretax profit from GBP42.2 million a year before and a 4.6% decline on the top line from GBP350.2 million.

"[Pig Improvement Co] ex-China performed robustly, with North America, Latin America and Europe delivering adjusted operating profit growth in constant currency. China continues to be a challenging porcine market, however our enhanced commercial focus has resulted in winning new royalty customers in the period which will positively impact fiscal year 2025 and beyond," Genus added.

PIC sales comprise semen, embryos and breeding animals with 'superior' genetics to those animals currently on farms.

Genus said: "With regards to our PRP programme, recent engagement with the US Food & Drug Administration has shifted to the post-approval compliance procedures. This has clarified the data submissions and monitoring that will be required on an ongoing basis post-PRP approval. Validation of our procedures to comply with these monitoring requirements is expected to take several months. We therefore now expect FDA approval in fiscal year 2025. Our dialogue shifting to the post-approval compliance procedures reinforces our view that approval will be forthcoming. There are no changes to our commercialisation timeline or financial projections."

Genus's PRP programme focuses on pigs who are resistant to porcine reproductive and respiratory syndrome, or PRRS. Genus has developed a solution to protect pigs from the PRRS virus, which causes animal suffering and prematurely kills millions of pigs every year.

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
24 Nov 2021 09:56

Genus shares slump 13% due to Chinese pig market challenges

Genus shares slump 13% due to Chinese pig market challenges

Read more
24 Nov 2021 09:13

LONDON MARKET OPEN: US President Biden unable to stop rising oil price

LONDON MARKET OPEN: US President Biden unable to stop rising oil price

Read more
24 Nov 2021 07:54

Genus sees FY profit 'moderately' below its expectations

(Sharecast News) - Animal genetics company Genus said on Wednesday that based on current trading, especially in China, pre-tax profit for 2022 is set to be "moderately lower" than its previous expectations.

Read more
17 Nov 2021 16:01

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
11 Nov 2021 15:49

UK dividends calendar - next 7 days

UK dividends calendar - next 7 days

Read more
15 Sep 2021 09:39

LONDON BROKER RATINGS: HSBC lifts Compass to Buy; RBC cuts JTC

LONDON BROKER RATINGS: HSBC lifts Compass to Buy; RBC cuts JTC

Read more
14 Sep 2021 19:36

IN BRIEF: Genus Chief Executive Wilson sells GBP1.1 million in shares

IN BRIEF: Genus Chief Executive Wilson sells GBP1.1 million in shares

Read more
9 Sep 2021 17:02

LONDON MARKET CLOSE: Stocks fall as China factory gate inflation jumps

LONDON MARKET CLOSE: Stocks fall as China factory gate inflation jumps

Read more
9 Sep 2021 12:08

LONDON MARKET MIDDAY: FTSE 100 tumbles as mood sours ahead of ECB

LONDON MARKET MIDDAY: FTSE 100 tumbles as mood sours ahead of ECB

Read more
9 Sep 2021 09:37

LONDON BROKER RATINGS: Credit Suisse raises boohoo; Peel cuts Genus

LONDON BROKER RATINGS: Credit Suisse raises boohoo; Peel cuts Genus

Read more
9 Sep 2021 09:20

TOP NEWS: Genus may not meet medium-term goals, despite earnings rise

TOP NEWS: Genus may not meet medium-term goals, despite earnings rise

Read more
9 Sep 2021 08:42

LONDON MARKET OPEN: FTSE falls as ECB tapering feared; easyJet tumbles

LONDON MARKET OPEN: FTSE falls as ECB tapering feared; easyJet tumbles

Read more
9 Sep 2021 07:48

LONDON MARKET PRE-OPEN: Morrisons profit falls; Genus sees volatility

LONDON MARKET PRE-OPEN: Morrisons profit falls; Genus sees volatility

Read more
9 Sep 2021 07:36

Genus posts rise in FY profits but warns over hit to growth

(Sharecast News) - Animal genetics company Genus reported a jump in full-year profit and revenue on Thursday as it continued to win new customers, with growth in both of its business, but warned that recent volatility in the Chinese porcine market will dent growth.

Read more
2 Sep 2021 14:55

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.